Coreline Soft announced on May 28th that it will supply its AI-powered lung imaging pattern analysis software, 'AVIEW Lung Texture,' to the Taiwan branch of global pharmaceutical company Boehringer Ingelheim. This announcement follows Coreline Soft's recent joint bid with Nuance, a subsidiary of Microsoft.
Boehringer Ingelheim, one of the world's top 20 pharmaceutical companies, reported annual revenue of $27.7 billion in 2023 and is particularly strong in the respiratory disease sector. The company is actively integrating AI from the early stages of drug development, collaborating with technologies like MS Copilot and Amazon Web Services (AWS) to transition towards data-centric operations.
In Taiwan, Boehringer Ingelheim plans to deploy AVIEW Lung Texture across major hospitals to gather real-world data on the antifibrotic drug 'Ofev (nintedanib)' that is approved in Taiwan and to conduct a parallel clinical validation of 'Neranomilast.' The aim is to quickly identify patients with interstitial lung disease (ILD) or interstitial lung abnormalities (ILA) who meet clinical research criteria and to advance clinical studies of the next-generation antifibrotic drug, Neranomilast.
Coreline Soft intends to expand its collaboration with Boehringer Ingelheim in the development of new drugs, increasing product supply to cover key hospitals across Taiwan. The company plans to operate screening programs to help establish next-generation ILD treatments.
AVIEW Lung Texture is distinguished by its ability to analyze chest CT images within minutes, quantifying and classifying pulmonary fibrosis patterns. It integrates results with PACS and RIS in real-time and allows instant viewing via a web-based dedicated viewer, facilitating rapid data sharing and utilization among research teams and medical professionals. This enhances patient selection speed and allows researchers to quantitatively track treatment responses, optimizing the research environment.
Jinkook Kim, CEO of Coreline Soft, stated, "The direct purchase and distribution of AVIEW Lung Texture by Boehringer Ingelheim to major hospitals demonstrate the clinical reliability of Coreline Soft's AI technology. We aim to build a research ecosystem that enables early diagnosis of ILD patients and swift application of innovative treatments."
